Abstract
Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing
evidences link denosumab with benefits in cancer, an area of interest for those in
charge of the postmenopausal health. Denosumab has shown efficacy in the control of
bone loss associated with hypogonadic states created by chemotherapy in breast and
other cancers. Moreover, some studies reveal efficacy in reducing the progression
of metastases. A panel of experts from the Spanish Menopause Society has met to develop
usage recommendations based on the best available evidence.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Spanish Menopause Society. 2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis.Maturitas. 2013; 76: 99-107
- Sequential use of antiresorptives in younger women.Osteoporos Int. 2014; 25: 1191-1192
- Osteoimmunology: interactions of the bone and immune system.Endocr Rev. 2008; 29: 403-440
- Osteoprotegerin: multiple partners for multiple functions.Cytokine Growth Factor Rev. 2013; 24: 401-409
- Osteoclast differentiation and activation.Nature. 2003; 423: 337-342
- Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM Study Extension.J Bone Miner Res. 2014; ([Epub ahead of print])https://doi.org/10.1002/jbmr.2236
- Denosumab in postmenopausal women with low bone mineral density.N Engl J Med. 2006; 354: 821-831
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.Bone. 2008; 43: 222-229
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.J Clin Endocrinol Metab. 2011; 96: 394-402
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.Osteoporos Int. 2013; 24: 227-235
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.J Clin Endocrinol Metab. 2008; 93: 2149-2157
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.J Bone Miner Res. 2010; 25: 72-81
- Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.Obstet Gynecol. 2013; 121: 1291-1299
- Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.Osteoporos Int. 2014; 25: 1953-1961
- FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med. 2009; 361: 756-765
- Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.J Bone Miner Res. 2012; 27: 694-701
- The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.J Clin Endocrinol Metab. 2013; 98: 4483-4492
- Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.Menopause. 2013; 20: 130-137
- Denosumab for the treatment of osteoporosis: a systematic literature review.Reumatol Clin. 2013; 9: 42-52
http://www.proliahcp.com/pdf/dear_healthcare_professional_letter.pdf.
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?.Osteoporos Int. 2012; 23: 327-337
- Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.Osteoporos Int. 2010; 21: 837-846
- Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study.Menopause. 2014; 21: 25-32
- Effects of denosumab on fracture and bone mineral density by level of kidney function.J Bone Miner Res. 2011; 26: 1829-1835
- Position of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patients.Maturitas. 2013; 75: 294-300
- Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.J Clin Oncol. 2008; 26: 4875-4882
- Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.Clin Cancer Res. 2012; 18: 326-335
- Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.J Clin Oncol. 2010; 28: 5132-5139
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.Lancet. 2011; 377: 813-822
- Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.J Clin Oncol. 2011; 29: 1125-1132
- Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.Pharmacoeconomics. 2011; 29: 951-961
- Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.J Med Econ. 2012; 15: 3-14
- Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.Osteoporos Int. 2013; 24: 1491-1502
- Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.Pharmacoeconomics. 2011; 29: 895-911
- Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.Expert Rev Pharmacoecon Outcomes Res. 2013; 13: 19-28
- Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.Appl Health Econ Health Policy. 2013; 11: 485-497
- Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.Bone. 2014; 59: 105-113
- Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.J Manag Care Pharm. 2011; 17: 621-643
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.J Med Econ. 2013; 16: 19-29
- Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.Clin Breast Cancer. 2012; 12: 247-258
- Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.Clin Ther. 2012; 34: 1334-1349
- Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.Health Technol Assess. 2013; 17: 1-386
- Comparing cost-effectiveness analyse s of denosumab versus zoledronic acid for the treatment of bone metastases.Support Care Cancer. 2013; 21: 1785-1791
Article info
Publication history
Published online: June 19, 2014
Accepted:
June 13,
2014
Received:
June 10,
2014
Identification
Copyright
© 2014 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
